CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced it will attend each
of the following upcoming healthcare conferences:
- Deutsche Bank 43rd Annual Health Care
Conference: The company will participate in 1x1 meetings on
Wednesday, May 9 in Boston, Mass.
- Bank of America Merrill Lynch 2018 Health Care Conference: The
company will present a corporate overview on Thursday, May 17 at 8:55
a.m. PT in Las Vegas, Nev.
A live audio webcast of the Bank of America Merrill Lynch presentation
will be available under the “Investors and Media” section of Seres’
website. A replay will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C.
difficile infection. Seres’ clinical candidate SER-287 has successfully
completed a Phase 1b study in patients with mild-to-moderate Ulcerative
Colitis. Seres is also developing SER-262, the first ever synthetic
microbiome therapeutic candidate, in a Phase 1b study in patients with
primary C. difficile infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180504005099/en/
Source: Seres Therapeutics, Inc.
Carlo Tanzi, Ph.D., 617-203-3467
President, Investor Relations and Corporate Communications